A Study to Investigate THT140, in Subjects With Advanced Solid Tumors and Lymphoma
A Phase 1/2, Open-label, Multicenter Study to Investigate the Safety, Pharmacokinetics, and Efficacy of THT140, an Oral PLK1 Inhibitor, in Subjects With Advanced Solid Tumors and Lymphoma
This is a 2-part, phase 1/2, open-label, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, pharmacogenomics, and efficacy of THT40 administered orally daily. This study consists of Phase 1 and Phase 2 components in subjects with advanced solid tumors and lymphoma with a focus on tumors with ARID1A and similar mutations who have progressed despite having received standard therapy or for whom no standard therapy exists.
調査の概要
詳細な説明
Phase 1 part of the study will consist of a dose-escalation and a dose-finding component. Phase 1 also includes expansion cohorts for subject with ARID1A and similar mutations.
Phase 2 will enroll subjects with locally advanced, recurrent, or metastatic, histologically confirmed advanced solid tumors or lymphoma, who have failed all standard therapies or for whom standard therapy does not exist, into 8 groups:
Group 1: Bladder cancer
Group 2: Breast cancer: Triple-negative breast cancer (TNBC)
Group 3: Lung cancer (non-small cell lung cancer [NSCLC] and small cell lung cancer [SCLC])
Group 4: Hepatocellular carcinoma (HCC) and biliary tract cancer (BTC)
Group 5: Metastatic colorectal cancer (mCRC) including KRAS-mutated mCRC
Group 6: B-cell lymphoma including diffuse large B-cell lymphoma (DLBCL)
Group 7: T-cell lymphoma (cutaneous T-cell lymphoma [CTCL] and peripheral T-cell lymphoma [PTCL])
Group 8: Basket cohort: tumor types that are suspected to have a related mechanism of action but are not included in previous groups including, esophageal, prostate, ovarian and pancreatic cancers
研究の種類
入学 (推定)
段階
- フェーズ2
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:Mark H Kirschbaum, MD
- 電話番号:626-316-3394
- メール:mark.kirschbaum@tethrabio.com
研究連絡先のバックアップ
- 名前:Jason Summa
- メール:jason.summa@tethrabio.com
研究場所
-
-
New York
-
New York、New York、アメリカ、10065
- 募集
- Memorial Sloan Kettering Cancer Center (MSKCC)
-
コンタクト:
- Horwitz Steven, MD
- 電話番号:+1 646-608-2680
- メール:Horwitzs@mskcc.org
-
-
Texas
-
Houston、Texas、アメリカ、77030
- 募集
- MD Anderson Cancer Center
-
コンタクト:
- Rabia Khan
- 電話番号:+1 713-563-4667
- メール:RKhan@mdanderson.org
-
-
Washington
-
Seattle、Washington、アメリカ、98109
- 募集
- Fred Hutchinson Cancer Center/ University of Washington
-
コンタクト:
- Gentry GT King, MD
- メール:gking@fredhutch.org
-
-
-
-
-
Barcelona、スペイン
- まだ募集していません
- Hospital Universitario Vall d'Hebron
-
コンタクト:
- Maria Vieito, MD
- メール:Mvieito@vhio.net
-
-
-
-
-
Seoul、韓国
- まだ募集していません
- Seoul National University Hospital
-
コンタクト:
- Do-Youn Oh, Prof. MD
- 電話番号:+82-2-2072-0701
- メール:ohdoyoun@snu.ac.kr
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Males or females aged ≥ 18 years.
-
Subjects with histological- or cytological-confirmed, advanced cancer who have progressed on (or not been able to tolerate) standard therapy or for whom no standard anticancer therapy exists
- For Phase 1, all tumor types may be enrolled
- For Phase 2, subjects will be enrolled as per the study design section above
-
ECOG performance status of 0-2.
-
Subjects who relapsed post-autologous or post-allogeneic transplant are eligible. Post-transplant subjects must be without active fungal disease or significant acute graft-versus-host disease
-
Women of childbearing potential (WOCBP) must have a negative pregnancy test (urine or serum) within 7 days prior to starting the study drug. Both males and females must agree to use effective birth control during the study (prior to the first dose and for 6 months after the last dose) if conception is possible during this interval.
-
Subjects must be able to swallow and retain orally administered medication and not have any clinically significant GI abnormalities that may alter the absorption, such as malabsorption syndrome or major resection of the stomach or bowels.
-
Able to agree to and sign the informed consent and to comply with the protocol.
Exclusion Criteria:
-
Subjects with a history of brain metastases or who have signs/symptoms attributable to brain metastases and have not been assessed with radiologic imaging to rule out the presence of brain metastases. Subjects with treated brain metastases that are asymptomatic and have been clinically stable for at least 4 weeks will be eligible.
-
Subjects who have not received vaccines for severe acute respiratory syndrome-corona virus-2 (SARS-COV-2) and have suspected signs and symptoms of the novel coronavirus infection (COVID-19) or have confirmed COVID-19.
-
Subjects with a history of another primary malignancy, other than:
- In situ carcinomas, e.g., breast, cervix, and prostate
- Locally excised nonmelanoma skin cancer
- No evidence of disease from another primary cancer for 2 or more years and has not taken any anti-cancer treatment in 2 years.
-
Any other clinically significant acute or chronic medical or psychiatric condition or any laboratory abnormality that may increase the risk associated with study drug administration or may interfere with the interpretation of study results.
-
Diseases that significantly affect GI absorption of THT140.
-
Subjects who have impaired cardiac function or clinically significant cardiac disease.
-
Presence of active chronic inflammatory bowel disease (ulcerative colitis, Crohn's disease) or GI perforation within 6 months of enrollment
-
Presence of an active infection requiring intravenous antibiotics
-
Presence of known history of human immunodeficiency virus-1/2 with uncontrolled viral load and on medications that may interfere with metabolism
-
Presence of active hepatitis B virus (HBV) or hepatitis C virus (HCV).
-
Chemotherapy, biologic therapy, targeted therapy, immunotherapy, extended-field radiotherapy, or investigational agents within 5 half-lives or 3 weeks (whichever is shorter) prior to administration of first dose of study drug on Day 1 or have not recovered from the side effects of such therapy.
-
Major surgery/surgical therapy for any cause within 4 weeks of the first dose
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:順次割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Phase 1 Dose Escalation
Phase 1 = THT140 administered orally in escalating doses starting at 5mg QD M-F week 1 to 3 for 3 weeks of a 4 week cycle. Subsequent cohorts will escalate in dose and schedule until optimized phase 2 dose and schedule is achieved. |
THT140 is a highly selective, orally- and intravenously- available, ATP-competitive inhibitor of PLK1.
他の名前:
|
|
実験的:Phase 2
Phase 2 = Recommended THT140 phase 2 dose and schedule administered orally in 28-day cycles. |
THT140 is a highly selective, orally- and intravenously- available, ATP-competitive inhibitor of PLK1.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Maximum tolerated dose
時間枠:6 months
|
The incidence rate of dose-limiting toxicities (first cycle only) at each dose level |
6 months
|
|
Overall Response Rate (ORR)
時間枠:18 months
|
Assessment of response criteria according to RESIST, Lugano or mSWAT. |
18 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Adverse events
時間枠:24 months
|
Type, frequency, and severity of adverse drug reactions |
24 months
|
|
AUC
時間枠:6 months
|
THT140 plasma concentrations |
6 months
|
|
Cmax
時間枠:6 months
|
THT140 plasma concentrations |
6 months
|
|
Tmax
時間枠:6 months
|
THT140 plasma concentrations |
6 months
|
|
T1/2
時間枠:6 months
|
THT140 plasma concentrations |
6 months
|
|
Disease Control Rate
時間枠:24 months
|
To evaluate the disease control rate (DCR) in subjects receiving THT140. |
24 months
|
|
Duration of Response
時間枠:24 months
|
To evaluate the duration of response (DOR) in subjects receiving THT140. |
24 months
|
|
Progression-free Survival
時間枠:24 months
|
To evaluate progression-free survival (PFS) in subjects receiving THT140. |
24 months
|
|
Overall Survival
時間枠:24 months
|
To evaluate overall survival (OS) in subjects receiving THT140. |
24 months
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Pharmacodynamics
時間枠:6 months
|
Pharmacodynamic response to THT140 will be assessed by mRNA sequencing of blood samples to determine differential expression of PLK1 target genes (including MYC, PLK1, CDKN1A) relative to baseline. |
6 months
|
|
Pharmacogenomics
時間枠:24 months
|
Genomic alterations will be assessed by next generation sequencing (NGS) at baseline and various time points during treatment with THT140 in order to investigate the relationship between genetic alterations in THT140 related pathways and response to THT140. Parameters of genetic variations (DNA mutations) and copy number variations using plasma cell-free DNA derived from peripheral blood will be assessed. |
24 months
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- THT140-101
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。